Literature DB >> 33000290

Hospital mortality in mechanically ventilated COVID-19 patients in Mexico.

Silvio A Ñamendys-Silva1,2, Alan Gutiérrez-Villaseñor3, Juan P Romero-González3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33000290      PMCID: PMC7527144          DOI: 10.1007/s00134-020-06256-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, As of August 13th, 2020, a total of 20,439,814 confirmed cases of coronavirus disease 2019 (COVID-19) have been reported to the World Health Organization, and 744,385 lives have been lost [1]. The Americas constitute the current epicentre of the COVID-19 pandemic. A total of 505,751 confirmed cases of COVID-19 and 55,293 deaths have been reported in Mexico [2], and 2.5% of these patients have required endotracheal intubation and invasive mechanical ventilation [2]. This report describes the sociodemographic characteristics and comorbidities associated with mortality in mechanically ventilated adults with COVID-19 in Mexico. We analysed data collected in the General Epidemiology Directorate of the Mexican Ministry of Heath, which is an open-source dataset comprising of daily updated data of suspected COVID-19 cases that were confirmed by a positive test for SARS-CoV-2 [2]. We used the version released on August 13th, 2020 [2]. A total of 12,018 mechanically ventilated adults with COVID-19 were included. The flow chart of the study is shown in Figure S1 (supplemental methods). The median age was 60 years (interquartile range 50–69; range 18–108 years), and 7971 (66.3%) were men (Figure S2) (supplementary material). The sociodemographic characteristics and comorbidities of the patients with COVID-19 (according to in-hospital deaths) are shown in Table 1. A total of 57.6% (n = 6928) of the patients were mechanically ventilated outside of the intensive care units (Figure S1) (supplementary material). The overall in-hospital mortality was 73.7% (n = 8861).
Table 1

Characteristics of mechanically ventilated COVID-19 patients, according to in-hospital death

CharacteristicsTotal population (n = 12,018)Survivors (n = 3157)Non-survivors (n = 8861)p value*
Age, years, median (interquartile range)60 (50–69)56 (46–66)61 (51–70) < 0.001
 18–34581 (4.8)270 (8.5)311 (3.5) < 0.001
 35–543740 (31.1)1188 (37.6)2551 (28.7)
 55–643313 (27.6)823 (26.1)2490 (28.1)
  ≥ 654384 (36.5)876 (27.7)3508 (39.6)
Female, n (%)4047 (33.7)1086 (34.4)2961 (33.4)0.315
Male, n (%)7971 (66.3)2071 (65.6)5900 (66.6)
Ability to speak a Mexican indigenous language, n (%)221 (1.8)41 (1.3)180 (2)0.009
Medical treatment in the public healthcare system, n (%)11,468 (95.4)2877 (91.1)8591 (96.9) < 0.001
Medical treatment in the private healthcare system, n (%)550 (4.6)280 (8.8)270 (3)
Time from illness onset to hospital admission > 6 days, n (%)3693 (30.7)1063 (33.7)2630 (29.7) < 0.001
Invasive mechanical ventilation outside intensive care unit, n (%)6928 (57.7)1714 (54.3)5214 (58.8) < 0.001
Invasive mechanical ventilation in the intensive care unit, n (%)5090 (42.3)1443 (45.7)3647 (41.1)
Comorbidities, n (%)
 Hypertension4802 (40)1109 (35.1)3693 (41.7) < 0.001
 Diabetes4349 (36.2)1019 (32.3)3330 (37.6) < 0.001
 Obesity3388 (28.2)895 (28.3)2493 (28.1)0.818
 Chronic kidney disease603 (5)137 (4.4)466 (5.3)0.042
 Cardiovascular disease590 (4.9)141 (4.5)449 (5)0.180
 Chronic obstructive lung disease463 (3.9)85 (2.6)378 (4.3) < 0.001
 Immunosuppression281 (2.3)62 (2)219 (2.5)0.105
 Asthma237 (2)55 (1.7)182 (2)0.279
 No comorbidities**3712 (30.9)1116 (35.3)2596 (29.3) < 0.001
  ≥ 1 comorbidity8306 (69.1)2041 (64.6)6265 (70.7)

*Chi-square (categorical variables) or Mann–Whitney (continuous variables) tests (α = 0.05)

**No comorbidities: patients had none of the listed comorbidities

Characteristics of mechanically ventilated COVID-19 patients, according to in-hospital death *Chi-square (categorical variables) or Mann–Whitney (continuous variables) tests (α = 0.05) **No comorbidities: patients had none of the listed comorbidities In our report, hospital mortality was higher than mortality in high-income countries such as the United Kingdom (67.4% versus 73.7%, p < 0.001) [3] and Germany (53% versus 73.7%, p < 0.001) [4]. Furthermore, hospitalisation in the public healthcare system presented higher crude mortality compared with the private healthcare system (Figure S3) (supplementary material). Mexican health authorities have stated that the response to the pandemic has been satisfactory because the health system has not been affected and because sufficient numbers of beds with ventilators are available. As shown in this report, the availability of sufficient numbers of beds with ventilators does not ensure improvement in the prognoses of patients with COVID-19. Beyond the quantity of beds with ventilators, there may also be concerns about the quality of care, as has been suggested by the high mortality rate for intubated COVID-19 patients in Mexico. Health care systems in low- and middle-income countries should be concerned about having sufficient qualified personnel (such as nurses and physicians) and other resources (such as personal protective equipment), which has been one of the main problems worldwide during the COVID-19 pandemic. The main limitation of this study is the use of a nationwide administrative database that was not designed for clinical research. However, it is useful to present the general overview of mechanically ventilated COVID-19 patients in Mexico. Additionally, we excluded patients who died outside of hospitals or who died before intubation. Below is the link to the electronic supplementary material. Supplementary file1 (PDF 256 kb)
  1 in total

1.  Cuvette and flow system for fast and sensitive spectrophotometric assays of oxygen consumption.

Authors:  L Mureşan; M Dânşoreanu; A Ana; A Bara; O Bârzu
Journal:  Anal Biochem       Date:  1980-05-01       Impact factor: 3.365

  1 in total
  17 in total

1.  In-hospital mortality in SARS-CoV-2 stratified by sex diffrences: A retrospective cross-sectional cohort study.

Authors:  Mohammed Al-Jarallah; Rajesh Rajan; Raja Dashti; Ahmad Al Saber; Peter A Brady; Hassan Abdelnaby; Moudhi Alroomi; Wael Aboelhassan; Mohammed Abdullah; Noor AlNasrallah; Bader Al-Bader; Haya Malhas; Maryam Ramadhan; Naser Alotaibi; Mohammad Al Saleh; Farah Almutairi; Kobalava D Zhanna
Journal:  Ann Med Surg (Lond)       Date:  2022-06-20

2.  Outcomes of Patients With Coronavirus Disease 2019 Receiving Organ Support Therapies: The International Viral Infection and Respiratory Illness Universal Study Registry.

Authors:  Juan Pablo Domecq; Amos Lal; Christopher R Sheldrick; Vishakha K Kumar; Karen Boman; Scott Bolesta; Vikas Bansal; Michael O Harhay; Michael A Garcia; Margit Kaufman; Valerie Danesh; Sreekanth Cheruku; Valerie M Banner-Goodspeed; Harry L Anderson; Patrick S Milligan; Joshua L Denson; Catherine A St Hill; Kenneth W Dodd; Greg S Martin; Ognjen Gajic; Allan J Walkey; Rahul Kashyap
Journal:  Crit Care Med       Date:  2021-03-01       Impact factor: 9.296

3.  Subphenotyping of Mexican Patients With COVID-19 at Preadmission To Anticipate Severity Stratification: Age-Sex Unbiased Meta-Clustering Technique.

Authors:  Lexin Zhou; Nekane Romero-García; Juan Martínez-Miranda; J Alberto Conejero; Juan M García-Gómez; Carlos Sáez
Journal:  JMIR Public Health Surveill       Date:  2022-03-30

4.  Projected impact of COVID-19 mitigation strategies on hospital services in the Mexico City Metropolitan Area.

Authors:  Zachary Fowler; Ellie Moeller; Lina Roa; Isaac Deneb Castañeda-Alcántara; Tarsicio Uribe-Leitz; John G Meara; Arturo Cervantes-Trejo
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

5.  Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data.

Authors:  Otavio T Ranzani; Leonardo S L Bastos; João Gabriel M Gelli; Janaina F Marchesi; Fernanda Baião; Silvio Hamacher; Fernando A Bozza
Journal:  Lancet Respir Med       Date:  2021-01-15       Impact factor: 30.700

Review 6.  Mechanical ventilation parameters in critically ill COVID-19 patients: a scoping review.

Authors:  Giacomo Grasselli; Emanuele Cattaneo; Gaetano Florio; Mariachiara Ippolito; Alberto Zanella; Andrea Cortegiani; Jianbo Huang; Antonio Pesenti; Sharon Einav
Journal:  Crit Care       Date:  2021-03-20       Impact factor: 9.097

7.  Residual lung damage following ARDS in COVID-19 ICU survivors.

Authors:  Nicola Compagnone; Diego Palumbo; George Cremona; Giordano Vitali; Rebecca De Lorenzo; Maria Rosa Calvi; Andrea Del Prete; Martina Baiardo Redaelli; Sabrina Calamarà; Alessandro Belletti; Stephanie Steidler; Caterina Conte; Alberto Zangrillo; Francesco De Cobelli; Patrizia Rovere-Querini; Giacomo Monti
Journal:  Acta Anaesthesiol Scand       Date:  2021-11-17       Impact factor: 2.274

8.  Tracheostomy timing and clinical outcomes in ventilated COVID-19 patients: a systematic review and meta-analysis.

Authors:  Yun Ji; Yumin Fang; Baoli Cheng; Libin Li; Xiangming Fang
Journal:  Crit Care       Date:  2022-02-08       Impact factor: 9.097

9.  Use of Airway Pressure Release Ventilation in Patients With Acute Respiratory Failure Due to COVID-19: Results of a Single-Center Randomized Controlled Trial.

Authors:  Miguel Á Ibarra-Estrada; Yessica García-Salas; Eduardo Mireles-Cabodevila; José A López-Pulgarín; Quetzalcóatl Chávez-Peña; Roxana García-Salcido; Julio C Mijangos-Méndez; Guadalupe Aguirre-Avalos
Journal:  Crit Care Med       Date:  2022-04-01       Impact factor: 9.296

10.  Inhibition of IP3R/Ca2+ Dysregulation Protects Mice From Ventilator-Induced Lung Injury via Endoplasmic Reticulum and Mitochondrial Pathways.

Authors:  Liu Ye; Qi Zeng; Maoyao Ling; Riliang Ma; Haishao Chen; Fei Lin; Zhao Li; Linghui Pan
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.